Genprex, Inc. (GNPX)

$1.4

-0.05 (-3.45%)
Rating:
Recommendation:
-
Symbol GNPX
Price $1.4
Beta -0.627
Volume Avg. 0.15M
Market Cap 67.058M
Shares () -
52 Week Range 1.17-3.62
1y Target Est -
DCF Unlevered GNPX DCF ->
DCF Levered GNPX LDCF ->
ROE -44.00% Strong Sell
ROA -47.78% Strong Sell
Operating Margin -
Debt / Equity 6.44% Neutral
P/E -
P/B 1.81 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GNPX news


Mr. J. Rodney Varner
Healthcare
Biotechnology
NASDAQ Capital Market

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.